Prognostic Value of Long Noncoding RNAs in Patients with Gastrointestinal Cancer: A Systematic Review and Meta-Analysis

Abstract

Gastrointestinal cancers (GICs) are a huge threat to human health, which mainly include esophageal, gastric, and colorectal cancers. The purpose of this study was to clarify the prognostic value of long noncoding RNAs (lncRNAs) in GICs. A total of 111 articles were included, and 13103 patients (3123 with esophageal cancer, 4972 with gastric cancer, and 5008 with colorectal cancer) were enrolled in this study. The pooled hazard ratio (HR) values and corresponding 95% confidence interval (95% CI) of overall survival (OS) related to different lncRNA expressions in esophageal, gastric, colorectal, and gastrointestinal cancer patients were 1.92 (1.70–2.16), 1.96 (1.77–2.16), 2.10 (1.87–2.36), and 2.00 (1.87–2.13), respectively. We have identified 74 lncRNAs which were associated closely with poor prognosis of GIC patients, including 58 significantly upregulated lncRNA expression and 16 significantly downregulated lncRNA expression. In addition, 47 of the included studies revealed relative mechanisms and 12 of them investigated the correlation between lncRNAs and microRNAs. Taken together, this meta-analysis supports that specific lncRNAs are significantly related to the prognosis of GIC patients and may serve as novel markers for predicting the prognosis of GIC patients. Furthermore, lncRNAs may have a promising contribution to lncRNA-based targeted therapy and clinical decision-making in the future.

<p>Discovering Biomarkers in Peritoneal Metastasis of Gastric Cancer by Metabolomics</p>

“…Compared with some single molecular markers, metabolic diagnostic markers are more comprehensive and accurate. [20][21][22][23][24][25][26][27][28][29][30][31][32][33] Metabolomics plays an important role in the screening of tumour biomarkers. A large number of studies have found potential biomarkers of gastric cancer, colorectal cancer, oesophageal cancer, liver cancer, ovarian cancer and other malignant tumours in blood, urine, tissue and other samples through metabolomics.…”

Long non-coding RNA RP11-284F21.9 functions as a ceRNA regulating PPWD1 by competitively binding to miR-769-3p in cervical carcinoma

“…LncRNAs show great diagnostic and prognostic values in multiple tumors [ 32 , 33 ]. In this study, we found that lncRNA RP11-284F21.9 was down-regulated in cervical cancer tissues and cell lines ( Figure 1 ), which could be used a novel biomarker for diagnosis and prognosis of cervical cancer.…”

The prognostic value of COL3A1/FBN1/COL5A2/SPARC-mir-29a-3p-H19 associated ceRNA network in Gastric Cancer through bioinformatic exploration

“…International Publisher months [2,3]. Despite great efforts such as surgery and adjuvant chemotherapy have been offered, the prognosis of GC patients has only slightly improved [4].…”

“…Gastric cancer (GC) remains the fifth most frequently malignancy and the third leading cause of cancer death worldwide especially in East Asia, and ranks as a growing health-threatening disease, causing over 1,000,000 new cases and approximately 783,000 deaths in 2018 worldwide 1 . Due to the lack of typical early symptoms, the majority of GC patients are diagnosed at advanced stages accompanied with malignant proliferation, extensive invasion and distant metastasis, with a median survival of only 3-5 months 2 , 3 . Despite great efforts such as surgery and adjuvant chemotherapy have been offered, the prognosis of GC patients has only slightly improved 4 .…”